Phase I Study of Induction Cisplatin, Docetaxel and Nintedanib for Stage IB-IIIA Non-small Cell Lung Cancers Amenable for Surgical Resection
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Nintedanib (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Jan 2018 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
- 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Aug 2017 Planned End Date changed from 1 Jun 2020 to 1 Apr 2020.